VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

Texas MPN Workshop 2022 | Momelotinib: a promising agent in MF

Srdan Verstovsek, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the promise of momelotinib for the treatment of myelofibrosis (MF), highlighting the ability of this agent to improve anemia in patients, as well as the size of the spleen. Dr Verstovsek also comments on the potential approval of this agent in the near future and the value of adding momelotinib to the MF treatment armamentarium. This interview took place at the third annual Texas MPN Workshop (TMW) 2022, held in San Antonio, TX.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter